The Relationship and Mechanism of CD27 with Coronary Atherosclerotic Heart Disease.

IF 3.1 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiovascular Drugs and Therapy Pub Date : 2025-08-08 DOI:10.1007/s10557-025-07740-y

Xue Fei Song, Fei Lin, Zhi Gang Chen, Guo An Zhao, Si Yu Sun, Jun Pu

{"title":"The Relationship and Mechanism of CD27 with Coronary Atherosclerotic Heart Disease.","authors":"Xue Fei Song, Fei Lin, Zhi Gang Chen, Guo An Zhao, Si Yu Sun, Jun Pu","doi":"10.1007/s10557-025-07740-y","DOIUrl":null,"url":null,"abstract":"<p><p>CD27, as a member of the immune checkpoints (IC), is physiologically expressed on various immune cells, with CD70 being its only known ligand. Together, they play a significant role in the co-stimulation and activation of T and B cells, regulating the body's immune response. Currently, the CD27/CD70 pathway shows great potential in the clinical treatment of tumors. Previous studies have found that immune checkpoint inhibitors (ICIs) provide significant benefits to cancer patients while also causing various adverse reactions, including cardiovascular diseases. The critical role of inflammation and adaptive immunity in coronary atherosclerotic heart disease (CAD) is widely recognized. Studies have found that the absence of CD27 or the blockade of the CD27/CD70 pathway exacerbates the occurrence of CAD. This review mainly summarizes the impact and mechanisms of CD27 and the CD27/CD70 pathway on CAD through immune regulatory pathways, providing important theoretical support for clinical treatment and prevention of adverse events in coronary heart disease, as well as new therapeutic strategies.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Drugs and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10557-025-07740-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

CD27, as a member of the immune checkpoints (IC), is physiologically expressed on various immune cells, with CD70 being its only known ligand. Together, they play a significant role in the co-stimulation and activation of T and B cells, regulating the body's immune response. Currently, the CD27/CD70 pathway shows great potential in the clinical treatment of tumors. Previous studies have found that immune checkpoint inhibitors (ICIs) provide significant benefits to cancer patients while also causing various adverse reactions, including cardiovascular diseases. The critical role of inflammation and adaptive immunity in coronary atherosclerotic heart disease (CAD) is widely recognized. Studies have found that the absence of CD27 or the blockade of the CD27/CD70 pathway exacerbates the occurrence of CAD. This review mainly summarizes the impact and mechanisms of CD27 and the CD27/CD70 pathway on CAD through immune regulatory pathways, providing important theoretical support for clinical treatment and prevention of adverse events in coronary heart disease, as well as new therapeutic strategies.

查看原文本刊更多论文

CD27与冠状动脉粥样硬化性心脏病的关系及机制

CD27作为免疫检查点（immune checkpoint， IC）的一员，在多种免疫细胞上有生理性表达，CD70是其唯一已知的配体。它们共同在T细胞和B细胞的共同刺激和激活中发挥重要作用，调节机体的免疫反应。目前，CD27/CD70通路在肿瘤的临床治疗中显示出巨大的潜力。先前的研究发现，免疫检查点抑制剂（ICIs）为癌症患者提供了显着的益处，同时也引起了各种不良反应，包括心血管疾病。炎症和适应性免疫在冠状动脉粥样硬化性心脏病（CAD）中的关键作用已被广泛认识。研究发现，缺乏CD27或阻断CD27/CD70通路会加剧CAD的发生。本文主要综述CD27及CD27/CD70通路通过免疫调节途径对冠心病的影响及机制，为临床治疗和预防冠心病不良事件以及制定新的治疗策略提供重要的理论支持。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular Drugs and Therapy 医学-心血管系统

CiteScore

8.30

自引率

0.00%

发文量

110

审稿时长

4.5 months

期刊介绍： Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field. Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients. Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.